C-Path (Critical Path Institute) optimizes drug and medical product development lifecycles by convening pharma, government, patient and academic organizations.

Core values

- **Accelerating Drug Development**: C-Path streamlines the drug development process, which leads to faster availability of life-changing medical products and therapies, particularly for rare and orphan diseases[1][3][5].
- **Improving Quality of Life**: By developing and endorsing biomarkers for diseases like Alzheimer’s, Parkinson’s, type 1 diabetes, kidney disease, and tuberculosis, C-Path contributes to better treatment outcomes and improved quality of life for patients[1][5].
- **Addressing Societal Needs**: C-Path addresses broad process inefficiencies in medical product development, enabling industry and academic scientists to focus on developing therapies that improve human health and well-being[1][3].
- **Promoting Positive Change**: The organization fosters precompetitive collaboration, data sharing, and regulatory partnerships, which are crucial for advancing medical innovation and regulatory science[1][3][5].
- **Community Well-being**: C-Path's work involves patient groups, caregivers, and advocacy organizations, ensuring that the development process is informed by and benefits those with the greatest need[1][3].